Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin
Authors
Keywords
-
Journal
Journal of Inflammation Research
Volume Volume 14, Issue -, Pages 6409-6419
Publisher
Informa UK Limited
Online
2021-11-30
DOI
10.2147/jir.s342846
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
- (2021) Sare Verstockt et al. INFLAMMATORY BOWEL DISEASES
- Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease
- (2021) Kei Nishioka et al. JOURNAL OF GASTROENTEROLOGY
- Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort
- (2021) Jennifer Ezirike Ladipo et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Oncostatin M Is a Prognostic Biomarker and Inflammatory Mediator for Sepsis
- (2020) Yi Gong et al. JOURNAL OF INFECTIOUS DISEASES
- Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease
- (2020) Lung-Yi Mak et al. Clinical and Translational Gastroenterology
- Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
- (2020) Natsuki Ishida et al. BMC GASTROENTEROLOGY
- Plasma Oncostatin-M, TNF-α, IL-7 and IL-13 network predicts Crohn’s disease response to Infliximab, as assessed by calprotectin log-drop.
- (2020) Beatriz Mateos et al. DIGESTIVE DISEASES
- Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases
- (2020) Amihai Rottenstreich et al. European Journal of Internal Medicine
- Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
- (2020) Lorenzo Bertani et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis
- (2020) Toer W. Stevens et al. Clinical Gastroenterology and Hepatology
- The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease
- (2020) Yi-Han Chen et al. Gastroenterology Research and Practice
- Biomarkers of inflammation in Inflammatory Bowel Disease: how long before abandoning single-marker approaches?
- (2020) Gabriele Dragoni et al. DIGESTIVE DISEASES
- Development of a simple, serum biomarker-based model predictive of the need for early biologic therapy in Crohn’s disease
- (2020) Danny Con et al. Journal of Crohns & Colitis
- Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease
- (2020) R Kalla et al. Journal of Crohns & Colitis
- Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
- (2019) Bram Verstockt et al. EBioMedicine
- Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases
- (2019) Anthony Buisson et al. Journal of Crohns & Colitis
- Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease
- (2019) Yugo Takaki et al. PEDIATRICS INTERNATIONAL
- ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detections of complications
- (2018) Christian Maaser et al. Journal of Crohns & Colitis
- Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis
- (2018) Alissa Walsh et al. Journal of Crohns & Colitis
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease
- (2017) Nathaniel R West et al. NATURE MEDICINE
- Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn’s disease
- (2017) Kyunghwan Oh et al. PLoS One
- The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease
- (2017) Lukasz Kwapisz et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease
- (2017) Athanasios Kostas et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Faecal biomarkers for screening small bowel inflammation in patients with Crohn’s disease: a prospective study
- (2017) Takahiro Shimoyama et al. Therapeutic Advances in Gastroenterology
- Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn’s Disease: A Retrospective Cohort Study
- (2017) Lei Ye et al. Scientific Reports
- Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy
- (2016) Rocio Ferreiro-Iglesias et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome
- (2014) MING-HUI CHANG et al. Molecular Medicine Reports
- Tailoring anti-TNF therapy in IBD: drug levels and disease activity
- (2014) Shomron Ben-Horin et al. Nature Reviews Gastroenterology & Hepatology
- Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies
- (2014) Tue Bennike WORLD JOURNAL OF GASTROENTEROLOGY
- European evidence based consensus for endoscopy in inflammatory bowel disease
- (2013) Vito Annese et al. Journal of Crohns & Colitis
- High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
- (2013) Fernando Magro et al. Journal of Crohns & Colitis
- Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn’s Disease: Partial Benefit by Infliximab—A Pilot Study
- (2012) Dario Sorrentino et al. DIGESTIVE DISEASES AND SCIENCES
- Fecal HMGB1 Is a Novel Marker of Intestinal Mucosal Inflammation in Pediatric Inflammatory Bowel Disease
- (2011) Roberta Vitali et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Fecal calprotectin is a predictive marker of relapse in Crohnʼs disease involving the colon: a prospective study
- (2010) Lamia Kallel et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease
- (2008) R. Berni Canani et al. DIGESTIVE AND LIVER DISEASE
- C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
- (2008) M Henriksen et al. GUT
- Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies
- (2007) Alain M. Schoepfer et al. INFLAMMATORY BOWEL DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search